TY - JOUR
T1 - Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia.
AU - Adams, V. R.
AU - Brenner, T.
PY - 1999
Y1 - 1999
N2 - Oprelvekin decreases the need for platelet transfusion in nontransplant patients receiving myelosuppressive chemotherapy. Until pharmacoeconomics studies determine the most cost-effective strategy for use of oprelvekin, it is likely to be used primarily in patients receiving dose-intensive chemotherapy to maintain the high-dose regimen that may provide a survival advantage for the patient with cancer. Additional product information is available at www.ahp.com/products/neumega.htm.
AB - Oprelvekin decreases the need for platelet transfusion in nontransplant patients receiving myelosuppressive chemotherapy. Until pharmacoeconomics studies determine the most cost-effective strategy for use of oprelvekin, it is likely to be used primarily in patients receiving dose-intensive chemotherapy to maintain the high-dose regimen that may provide a survival advantage for the patient with cancer. Additional product information is available at www.ahp.com/products/neumega.htm.
UR - http://www.scopus.com/inward/record.url?scp=0033195411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033195411&partnerID=8YFLogxK
U2 - 10.1016/S1086-5802(15)30363-6
DO - 10.1016/S1086-5802(15)30363-6
M3 - Article
C2 - 10533354
AN - SCOPUS:0033195411
SN - 1086-5802
VL - 39
SP - 706
EP - 707
JO - Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)
JF - Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)
IS - 5
ER -
